NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. The underwritten public offering is valued at $60 million of Krystal Biotech's common stock.
The capital raised will be used for various activities, including advancing clinical trials, research, manufacturing practices and working capital.
Chardan has participated in advisory and capital raising transactions totaling more than $2 billion in 2018.
Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
Learn more about Chardan: www.chardan.com
Emily Levine, Chardan
Tom Rozycki, Prosek Partners